Severe impairment of patient‐reported outcomes in patients with chronic hepatitis C virus infection seen in real‐world practices across the world: Data from the global liver registry. Issue 11 (7th September 2022)

• Record Type: Journal Article
• Authors: Younossi, Zobair M.; Yu, Ming‐Lung; El‐Kassas, Mohamed; Esmat, Gamal; Castellanos Fernández, Marlen I.; Buti, Maria; Papatheodoridis, Georgios; Yilmaz, Yusuf; Isakov, Vasily; Duseja, Ajay; Méndez‐Sánchez, Nahum; Hamid, Saeed; Gordon, Stuart C.; Romero‐Gómez, Manuel; Chan, Wah‐Kheong; Ong, Janus P.; Younossi, Issah; Lam, Brain; Ziayee, Mariam; Nader, Fatema; Racila, Andrei; Henry, Linda; Stepanova, Maria
• Is Part Of: Journal of viral hepatitis. Volume 29:Issue 11(2022)
• Page Start: 1015
• Page End: 1025
• Publication Date: 2022-09-07
• Subjects: direct‐acting antivirals -- disease burden -- quality of life -- viral hepatitis -- work productivity; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.13741
• Languages: English
• ISSNs: 1352-0504

Abstract

Abstract: Cure of chronic hepatitis C (CHC) can lead to improvement of health‐related quality of life and other patient‐reported outcomes (PROs). While extensive PRO data for CHC patients who were enrolled in clinical trials are available, similar data for patients seen in real‐world practices are scarce. Our aim was to assess PROs of CHC patients enrolled from real‐world practices from different regions and to compare them with those enrolled in clinical trials. CHC patients seen in clinical practices and not receiving treatment were enrolled in the Global Liver Registry (GLR). Clinical and PRO (FACIT‐F, CLDQ‐HCV, WPAI) data were collected and compared with the baseline data from CHC patients enrolled in clinical trials. N = 12, 171 CHC patients were included (GLR n = 3146, clinical trial subjects n = 9025). Patients were from 30 countries from 6 out of 7 Global Burden of Disease (GBD) super‐regions. Compared with clinical trial enrollees, patients from GLR were less commonly enrolled from High‐Income GBD super‐region, older, more commonly female, less employed, had more type 2 diabetes, anxiety and clinically overt fatigue but less cirrhosis (all p < 0.001). Out of 15 PRO domain and summary scores, 12 were lower in GLR patients than in subjects enrolled in clinical trials ( p < 0.001). In multiple regression models, anxiety, depression, and fatigue were associated with significant PRO impairment in CHC patients ( p < 0.05). After adjustment for the clinico‐demographic confounders, the association of PRO scores of CHC patients with enrolment settings was no longer significant (all p > 0.05). In conclusion, hepatitis C patients seen in the real‐world practices have PRO impairment driven by fatigue and psychiatric comorbidities.